

# Peptidpharmakologie und klinische Aspekte (in chronologischer Abfolge)

- (348) **Intermittent administration of the circulating form of human parathyroid hormone (hPTH-1-37) prevents bone loss in ovariectomized rats.** (2007) Stephan S, van de Fliedt J, Loumi S, Bonaterra G, Kramer FJ, Fehr M, Tillmann HC, Forssmann WG, Maronde E. *Eur J Med Res*. **12**: 13-20.
- (341) **Haemodynamic and clinical effects of ularitide in decompensated heart failure.** (2006) Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Luss H, Meyer M. *Eur Heart J*. **27**: 2823-32.
- (334) **Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial.** (2005) Mitrovic V, Luss H, Nitsche K, Forssmann K, Maronde E, Fricke K, Forssmann WG, Meyer M. *Am Heart J*. **150**: 1239.
- (309) **Survival of severe ARDS with five-organ system failure following burns and inhalation injury in a 15-year-old patient.** (2003) Cedidi C, Hierner R, Pichlmaier M, Forssmann WG, Meyer M. *Burns*. **29**: 389-94.
- (308) **Is serotonin significant for the control of penile flaccidity and detumescence in the human male?** (2003) Uckert S, Fuhlenriede MH, Becker AJ, Stief CG, Scheller F, Knapp WH, Forssmann Wg, Jonas U. *Urol Res*. **31**: 55-60.
- (296) **Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179.** (2002) Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schidt B, Tsikas D, Boger RH, Forssmann WG, Drexler H, Schieffer B. *Circ Res*. **90**: 770-6.
- (281) **Recollections and memorial for René G. Favaloro – Inventor of coronary bypass operation.** (2001) Aoki A, Forssmann WG, Haverich A. *Eur J Med Res* **6**: 369–371.
- (278) **The renal urodilation system: clinical implications.** (2001) Forssmann WG, Meyer M, Forssmann K. *Cardiovasc Res* **51**: 450–62.
- (270) **Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs.** (2001) Padilla F, Garcia-Dorado D, Agullo L, Barrabes JA, Inserte J, Escalona N, Meyer M, Mirabet M, Pina P, Soler-Soler J. *Cardiovasc Res* **51**: 592–600.
- (249) **Rectus abdominis musculoperitoneal flap for closure of bladder defect.** (2000) Schilling MK, Forssmann U, Kollmar O, Maurer CA, Buchler MW. *J Urol* **163**: 1517.
- (246) **Conservative surgical treatment of diffuse peritonitis.** (2000) Seiler CA, Brugger L, Forssmann U, Baer HU, Buchler MW. *Surgery* **127**: 178–184.
- (242) **Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue.** (2000) Stief CG, Uckert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, Jonas U. *Urology* **55**: 146–50.

- (239) **Urodilatin (pINN: Ularitide) reverses acute renal failure following cardiac surgery.** (2000) Wiebe K, Meyer M, Wahlers T, Zenker D, Schulz FP, Mohr F, Michels P, Forssmann WG. *Eur J Med Res* 1: 1–7.
- (235) **Fibroblast growth factor protects the kidney against ischemia–reperfusion injury.** (1999) Cuevas P, Martinez–Coso V, Fu X, Orte L, Reimers D, Gimenez–Gallego G, Forssmann WG, Saenz De Tejada I. *Eur J Med Res* 4: 403–10.
- (233) **Bronchodilation using combined urodilatin – albuterol administration in asthma: a randomized, double–blind, placebo–controlled trial.** (1999) Fluge T, Forssmann WG, Kunkel G, Schneider B, Mentz P, Forssmann K, Barnes PJ, Meyer M. *Eur J Med Res* 4: 411–5.
- (218) **Therapeutic use of the natriuretic peptide ularitide in acute renal failure.** (1999) Meyer M, Pfarr E, Schirmer G, Uberbacher HJ, Schope K, Bohm E, Fluge T, Mentz P, Scigalla P, Forssmann WG. *Ren Fail* 21: 85–100.
- (217) **Variability in the ratio of mutant to wildtype myosin heavy chain present soleus muscle of patients with familial hypertrophic cardiomyopathy.** (1999) Nier V, Schultz I, Brenner B, Forssmann WG, Raida M. *FEBS Lett* 461: 246–52.
- (202) **The effect of the specific phosphodiesterase–IV–inhibitor rolipram on the ureteral peristalsis of the rabbit in vitro and in vivo.** (1998) Becker AJ, Stief CG, Meyer M, Truss MC, Forssmann WG, Jonas U. *J Urol* 160: 920–5.
- (198) **Radiocontrast–induced natriuresis associated with increased urinary urodilatin excretion.** (1998) Haller C, Meyer M, Scheele T, Koch A, Forssmann WG, Kubler W. *J Intern Med* 243: 155–62.
- (192) **A new immunoenzymometric assay for bioactive N–terminal human parathyroid hormone fragments and its application in pharmacokinetic studies in dogs.** (1998) Magerlein M, Hock D, Adermann K, Muller–Beckmann B, Neidlein R, Forssmann WG, Stein K. *Arzneimittelforschung* 48: 199–204.
- (191) **Production of sequence specific polyclonal antibodies to human parathyroid hormone 1–37 by immunization with multiple antigenic peptides.** (1998) Magerlein M, Hock D, Adermann K, Neidlein R, Forssmann WG, Strein K. *Arzneimittelforschung* 48: 783–7.
- (187) **Urinary and plasma urodilatin measured by a direct RIA using a highly specific antiserum.** (1998) Meyer M, Armbruster FP, Maier I, Schwing J, Haller C, Missbichler A, Adermann K, Forssmann WG, Woloszczuk W. *Clin Chem* 44: 2524–9.
- (186) **Urodilatin, a natriuretic peptide with clinical implications.** (1998) Meyer M, Richter R, Forssmann WG. *Eur J Med Res* 3: 103–110.
- (178) **Is urodilatin the missing link in exercise–dependent renal sodium retention?** (1998) Schmidt W, Bub A, Meyer M, Weiss T, Schneider G, Maassen N, Forssmann WG. *J Appl Physiol* 84: 123–8.
- (176) **Urinary excretion of urodilatin in healthy children and children with renal disease.** (1998) Seeman T, Meyer M, Schmitt CP, Remer T, Forssmann WG, Scharer K. *Pediatr Nephrol* 12: 55–9.
- (162) **Effects of sodium nitroprusside in the rat cortical collecting duct are independent of the NO pathway.** (1997) Hirsch JR, Cermak R, Forssmann WG, Kleta R, Kruhoffer M, Kuhn M, Schafer JA, Sun D, Schlatter E. *Kidney Int* 51: 473–6.

- (156) **Prophylactic use of low-dose urodilatin for prevention of renal impairment following liver transplantation: a randomized placebo-controlled study.** (1997) Langrehr JM, Kahl A, Meyer M, Neumann U, Knoop M, Jonas S, Steinmuller T, Bechstein WO, Frei U, Forssmann WG, Neuhaus P. *Clin Transplant* **11**: 593–8.
- (151) **Urodilatin (INN: ularitide) as a new drug for the therapy of acute renal failure following cardiac surgery.** (1997) Meyer M, Wiebe K, Wahlers T, Zenker D, Schulze FP, Michels P, Forssmann WG. *Clin Exp Pharmacol Physiol* **24**: 374–6.
- (146) **Natriuresis after cardiopulmonary bypass: relationship to urodilatin, atrial natriuretic factor, antidiuretic hormone, and aldosterone.** (1997) Sehested J, Wacker B, Forssmann WG, Schmitzer E. *J Thorac Cardiovasc Surg* **114**: 666–71.
- (140) **General anesthesia for ureteral measurements in the rabbit.** (1996/97) Becker AJ, Stief CG, Truss MC, Meyer M, Forssmann WG, Jonas U. *J Exp Anim Sci* **38**: 93–100.
- (139) **Stickoxid (NO) als möglicher Neurotransmitter in der Tonusregulation des Ureters.** (1996/97) Uckert S, Stief CG, Truss M, Meyer M, Forssmann WG, Jonas U. *Akt Urol* **26**: 10–12.
- (136) **Secretion of a urodilatin-like immunoreactive (URO-like-IR) substance from a human kidney cell line (HEK-293).** (1996) Bub A, Rechkemmer G, Hock D, Forssmann WG. *Eur J Med Res* **1**: 479–83.
- (135) **Urodilatin secretion in salt-loaded Wistar rats.** (1996) Bub A, Rechkemmer G, Hock D, Forssmann WG. *Eur J Med Res* **1**: 417–24.
- (124) **Urodilatin (INN: ularitide). A new peptide in the treatment of acute kidney failure following liver transplantation.** (1996) Kuse ER, Meyer M, Constantin R, Oldhafer K, Schlitt HJ, Schulz-Knappe P, Uberbacher HJ, Pichlmayr R, Forssmann WG. *Anaesthesist* **45**: 351–8.
- (123) **Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: urodilatin (INN: Ularitide), VIP, and PACAP.** (1996) Meyer M, Fluge T, Kruhoffer M, Forssmann WG. *Ann N Y Acad Sci* **805**: 443–61.
- (122) **The renal paracrine peptide system--possible urologic implications of urodilatin.** (1996) Meyer M, Stief CG, Becker AJ, Truss MC, Taher A, Jonas U, Forssmann WG. *World J Urol* **14**: 375–9.
- (121) **Ularitide: from renal natriuretic peptide to clinical trials.** (1996) Meyer M, Uberbacher HJ, Bohm E, Schope KB, Brett W, Forssmann WG. *Curr Opin Nephrol Hypertens* **5**: 364–8.
- (120) **Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects.** (1996) Meyer M, Richter R, Brunkhorst R, Wrenger E, Schulz-Knappe P, Kist A, Mentz P, Brabant EG, Koch KM, Rechkemmer G, Forssmann WG. *Am J Physiol* **271**: F489–97.
- (115) **Urinary excretion of urodilatin in patients with cirrhosis.** (1996) Salo J, Jimenez W, Kuhn M, Gines A, Gines P, Fernandez-Esparrach G, Angeli P, Claria J, Bataller R, Arroyo V, Forssmann WG, Rodes J. *Hepatology* **24**: 1428–32.
- (102) **Acute renal failure following cardiac surgery is reverted by administration of Urodilatin (INN: Ularitide).** (1996) Wiebe K, Meyer M, Wahlers T, Zenker D, Schulze F, Michels P, Dalichau H, Mohr FW, Borst H, Forssmann WG. *Eur J Med Res* **1**: 259–65.

- (098) Significance of prophylactic urodilatin (INN: ularitide) infusion for the prevention of acute renal failure in patients after heart transplantation.** (1995) Brenner P, Meyer M, Reichenspurner H, Meiser B, Muller R, Mentz P, Schulz-Knappe P, Uberbacher HJ, Kreuzer E, Uberfuhr P, Guder WG, Wenzlaff H, Teschemacher H, Reinart B, Forssmann WG. *Eur J Med Res* 1: 137-43.
- (093) Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure.** (1995) Elsner D, Muders F, Muntze A, Kromer EP, Forssmann WG, Riegger GA. *Am Heart J* 129: 766-73.
- (092) Effects of urodilatin in the rat kidney: comparison with ANF and interaction with vasoactive substances.** (1995) Endlich K, Forssmann WG, Steinhausen M. *Kidney Int* 47: 1558-68.
- (089) Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics.** (1995) Fluge T, Fabel H, Wagner TO, Schneider B, Forssmann WG. *Regul Pept* 59: 357-70.
- (088) Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects.** (1995) Fluge T, Fabel H, Wagner TO, Schneider B, Forssmann WG. *Eur J Clin Invest* 25: 728-36.
- (087) Urodilatin (ularitide, INN): a renal natriuretic peptide. Molecular biology and clinical importance.** (1995) Forssmann WG. *Nephron* 69: 211-22.
- (080) Treatment of acute renal failure with urodilatin after unrelated bone marrow transplantation in an 18-month-old boy.** (1995) Laws HJ, Kropp S, Meyer M, Forssmann WG, Burdach S. *Bone Marrow Transplant* 16: 307-10.
- (076) Urodilatin (pINN: Ularitide) is a new drug for prevention and treatment of postoperative acute renal failure.** (1995) Meyer M, Mentz P, Agrawal B, Schopke K, Forssmann WG. *Drugs of the Future* 20: 490-498.
- (075) Urodilatin. Use of a new peptide in intensive care.** (1995) Meyer M, Schulz-Knappe P, Kuse ER, Hummel M, Hetzer R, Pichlmayr R, Forssmann WG. *Anaesthesist* 44: 81-91.
- (071) Analysis of rare HLA-DRB1-DQB1 haplotypes in kidney donors and recipients.** (1995) Scherer S, Mytilineos J, Forssmann U, Dunckley H, Trejaut J, Chapman J, Middleton D, Opelz G. *Transplant Proc* 27: 684-5.
- (063) Urodilatin: a new approach for the treatment of therapy-resistant acute renal failure after liver transplantation.** (1994) Cedidi C, Meyer M, Kuse ER, Schulz-Knappe P, Ringe B, Frei U, Pichlmayr R, Forssmann WG. *Eur J Clin Invest* 24: 632-9.
- (059) Localization of the bronchodilator effect induced by type A natriuretic peptide in asthmatic subjects.** (1994) Fluge T, Fabel H, Wagner TO, Forssmann WG. *Clin Investig* 72: 772-4.
- (058) Type A natriuretic peptides exhibit different bronchoprotective effects in rats.** (1994) Fluge T, Hoymann HG, Hohlfeld J, Heinrich U, Fabel H, Wagner TO, Forssmann WG. *Eur J Pharmacol* 271: 395-402.
- (057) A method for HLA-DQA typing by the PCR-SSP technique.** (1994) Forssmann U, Mytilineos J, Scherer S, Opelz G. *Transpl Int* 7: 515-8.

**(056) Urodilatin: from cardiac hormones to clinical trials.** (1994) Forssmann WG, Meyer M, Schulz-Knappe P. *Exp Nephrol* 2: 318–23.

**(055) Healing of tubal anastomoses--microsurgery vs. fibrin gluing: morphologic aspects.** (1994) Gauwerky JF, Klose RP, Forssmann WG. *Zentralbl Gynakol* 116: 173–8.

**(054) Hydrosalpinx formation and its regeneration after microsurgical reconstruction--a functional and morphological study on rabbits.** (1994) Gauwerky JF, Forssmann WG, Kurz M, Klose RP, Bastert G. *Hum Reprod* 9: 2090–102.

**(044) Amplification of gene fragments with very high G/C content: c7dGTP and the problem of visualizing the amplification products.** (1994) Weiss J, Zucht HD, Forssmann WG. *PCR Methods Appl* 4: 124–5.

**(043) Treatment of acute postoperative renal failure after liver and heart transplantation by urodilatin.** (1993) Cedidi C, Kuse ER, Meyer M, Oldhafer K, Ringe B, Wahlers T, Cremer J, Frei U, Pichlmayr R, Forssmann WG. *Clin Investig* 71: 435–6.

**(041) Development and application of a urodilatin (CDD/ANP-95-126)-specific radioimmunoassay.** (1993) Drummer C, Fiedler F, Bub A, Kleefeld D, Dimitriades E, Gerzer R, Forssmann WG. *Pflugers Arch* 423: 372–7.

**(039) Urodilatin, a new therapy to prevent kidney failure after heart transplantation.** (1993) Hummel M, Kuhn M, Bub A, Mann B, Schneider B, von Eickstedt KW, Forssmann WG, Hetzer R. *J Heart Lung Transplant* 12: 209–17.

**(035) Intracavernous application of SIN-I in rabbit and man: functional and toxicological results.** (1993) Meyer M, Taher A, Krah H, Staubesand J, Becker AJ, Kircher M, Mayer B, Jonas U, Forssmann WG, Stief CG. *Ann Urol* 27: 179–82.

**(034) Impaired coronary dilator responses to substance P and impaired flow-dependent dilator responses in heart transplant patients with graft vasculopathy.** (1993) Mugge A, Heublein B, Kuhn M, Nolte C, Haverich A, Warnecke J, Forssmann WG, Lichtlen PR. *J Am Coll Cardiol* 21: 163–70.

**(029) Urodilatin: a new peptide with beneficial effects in the postoperative therapy of cardiac transplant recipients.** (1992) Hummel M, Kuhn M, Bub A, Bittner H, Kleefeld D, Marxen P, Schneider B, Hetzer R, Forssmann WG. *Clin Investig* 70: 674–82.

**(015) Effects of ANP-(95-126) in dogs before and after induction of heart failure.** (1990) Riegger GA, Elsner D, Forssmann WG, Kromer EP. *Am J Physiol* 259: H1643–8.

**(014) Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men.** (1990) Saxenhofer H, Raselli A, Weidmann P, Forssmann WG, Bub A, Ferrari P, Shaw SG. *Am J Physiol* 259: F832–8.